Page last updated: 2024-11-04

allantoin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID204
CHEMBL ID593429
CHEBI ID15676
SCHEMBL ID3208
MeSH IDM0000725

Synonyms (385)

Synonym
urea,5-dioxo-4-imidazolidinyl)-
avc/dienestrolcream
nsc-7606
mls000737882 ,
cordianine
glyoxyldiureid
nsc7606 ,
alantan
hydantoin, 5-ureido-
sebical
allantol
(2,5-dioxo-4-imidazolidinyl)urea
n-(2,5-dioxo-4-imidazolidinyl)urea
CHEBI:15676 ,
4-ureido-2,5-imidazolidinedione
2,5-dioxo-4-imidazolidinyl-urea
n-(2,5-dioxoimidazolidin-4-yl)urea
5-ureido-2,4-imidazolidindione
KBIO1_000281
DIVK1C_000281
NCI60_041675
SDCCGMLS-0066595.P001
1-(2,5-dioxoimidazolidin-4-yl)urea
einecs 202-592-8
nsc 7606
brn 0102364
allantoin [usan:ban]
allantoin (jan/usp)
D00121 ,
SPECTRUM_001078
OPREA1_621175
PRESTWICK_11
NCGC00016358-01
cas-97-59-6
(2,5-dioxoimidazolidin-4-yl)urea
BPBIO1_000005
PRESTWICK2_000002
PRESTWICK3_000002
BSPBIO_002551
BSPBIO_000003
epa pesticide chemical code 085701
(+/-)-allantoin
ccris 1958
ai3-15281
dl-allantoin
psoralon
urea, (2,5-dioxo-4-imidazolidinyl)- (9ci)
glyoxylic(acid) diureide
urea, (2,5-dioxo-4-imidazolidinyl)-
glyoxylic diureide
caswell no. 024
allantoin (8ci)
septalan
5-ureido-2,4-imidazolidindion
cutemol emollient
uniderm a
AB00052307
5-ureidohydantoin
ALLANTOIN ,
97-59-6
C01551
glyoxyldiureide
smr000528073
NCGC00094854-01
NCGC00094854-02
KBIO2_001558
KBIOGR_001271
KBIO2_006694
KBIOSS_001558
KBIO3_002051
KBIO2_004126
SPECTRUM2_000219
SPBIO_000237
SPECTRUM4_000716
SPBIO_001924
PRESTWICK1_000002
SPECTRUM3_000876
PRESTWICK0_000002
NINDS_000281
SPECTRUM1500801
SPECTRUM5_001526
IDI1_000281
NCGC00094854-04
NCGC00094854-03
MLS002473300
A999F0D6-0285-41D9-A6BA-B705987B663C
AC-11040
HMS2092K16
A0211
herpecin l
BMSE000437
HMS500O03
idelalisib metabolite m1a
alwextin
sd 101
CHEMBL593429
HMS1568A05
HMS1921I10
AKOS000120642
NCGC00094854-05
HMS2095A05
tox21_302912
NCGC00256403-01
dtxcid0043
dtxsid3020043 ,
NCGC00259636-01
tox21_202087
nsc757792
nsc-757792
pharmakon1600-01500801
tox21_110395
HMS2268N08
S3856
c4h6n4o3
CCG-39781
hsdb 7490
unii-344s277g0z
5-25-15-00338 (beilstein handbook reference)
urea, n-(2,5-dioxo-4-imidazolidinyl)-
ec 202-592-8
344s277g0z ,
allantoin [usan:usp:ban:jan]
FT-0604592
STL373778
allantoin [vandf]
allantoin [jan]
allantoin [hsdb]
allantoin [ii]
allantoin [usan]
allantoin [inci]
sd 101 [who-dd]
allantoin [ep monograph]
allantoin [usp-rs]
allantoin [mart.]
allantoin [usp monograph]
allantoin [who-dd]
allantoin [mi]
5-ureidohydantoin; glyoxyldiureide; glyoxylic diureide; cordianine; glyoxyldiureid; (2,5-dioxo-4-imidazolidinyl)urea
BBL027508
AKOS016038547
SCHEMBL3208
NCGC00094854-07
tox21_110395_1
5377-33-3
W-100104
fancol toin
n-(2,5-dioxo-4-imidazolidinyl)urea #
2,5-imidazolidinedione, 4-ureido-
component of skin-balm (salt/mix)
5-ureidohydrantoin
CS-7741
AB00052307_11
mfcd00005260
J-522839
n-(2,5-dioxo-4(1h)-imidazolidinyl)urea
allantoin, european pharmacopoeia (ep) reference standard
allantoin, analytical standard
SR-01000766252-4
SR-01000766252-3
sr-01000766252
SR-01000766252-2
allantoin, united states pharmacopeia (usp) reference standard
allantoin, >=98.0% (n)
allantoin, p.a., 98.5-101.0%
allantoin, pharmaceutical secondary standard; certified reference material
SBI-0051759.P002
HMS3712A05
5-ureido-hydantoin
HY-N0543
Q409804
DB11100
allation,(s)
AS-13865
AMY13912
5-ureidohydantoin;glyoxyldiureide
BCP31832
HMS3885M08
D85069
97-59-6 (racemic)
NCGC00094854-06
3-hydroxy-2-propyl-4-pentenoic acid ethyl ester
sodium methanethiolate (~20% in water)
EN300-21043
dl-allantoin-5-13c; 1-15n
mulberry emulsion
luminant umbrella mask pack
diabetic wound gel professional
gmdansu herbal mask sheet
cvs health advanced scar gel
nanomix nano cleanskin protectant antibacterial function
allantoin 0.5%
jilgyungyi (10 tablets)
bruise md
scar reducer
shelo nabel baba de caracol
well and good liquid bandage
leaders mediu pore cleaning carbonated pack
queen perfume hair conditioner
dgh advanced formula scar skin protectant
wound gel professional
dog mx bandage
secretipss scalp hair essential booster
raphagenpowde r
teevodar
reborncell cleansing
allantoin (usan:usp:ban:jan)
meijer scar gel
fikia marine delight soothing mist
smart brushing tooth
mandelic 2 peel gel
dr. young 2p pearl brightening balm spf35 pa
miracle gyn
walgreens advanced scar gel
luxury cell performance emulsion
qyo qyo tangerine bright moist mask pack
anti chafe balm
vet worthy liquid bandage
by pharmicell lab the prestige essence
noblesse manz grooming so clean care
cellapy mgf hydro gel intense mask
tamnamo vital hair treatment
allantoin (ep monograph)
iasobetic allantoin skin protectant
alantoina
scar cream
seaweed aqua massage
usepa/opp pesticide code: 085701
atobos baby aqua soothing
nano gold bio mask pack
vashti
dr. dog skin care for dogs
bioxidea miracle 48 excellence gold mask
pore care lotus mask
bioxidea element 48 natura diamond mask
shelo nabel baba de caracol locion corporal
inflammation otcradiation relief
cool melon
allantoin (usp monograph)
dr deep brightening facialemulsion
vital fluid i platinum anti wrinkle serum
bl vital skin
hairfill scalp hair essential booster
atobos wash
3ce fixer and mascara black
allantoin cream
botaneth pronoxin hair regainer fs2 activator 2-a 2-b
scar gel
pelo baum lash lash
calm and heal melting balm
leaders mediu calming peppermint pack
ultra soothing toner
dermaheal ultimatum ptx sports
dr deep aqua wrinkle
soosul essence
first honey burn salve
by pharmicell lab luxury cell performance toner
kenaf wet wipe
biowhite beauty serum
cetaphil soothing gel cream
diabetic wound gel
chamois glide
equate scartopical
lycoris rubus whitening
allantoin (mart.)
scarequate
3ce fixer and mascara brown
bioxidea miracle 48 excellence diamond mask
run guard sensitive
lycoris rubus whitening fluid
m-rose seaweed essence serum
hairfill scalp hair essential tonic plus
siseundeusi bless body
sarene soothing skin
ac control serum
noblrose foam cleanser
parma anus skin premium cleanser
plagentra baby bubble wash
by pharmicell lab luxury cell performance emulsion
advanced derma spray
secretipss scalp hair essential boosterintense care for damaged scalps and hairs
arc skin protectant
jabon shelo nabel con alantoina baba de caracol
miracle gyn (2 tablets)
bl vital essence
run guard original
miracle gyn (10 tablets)
luxury cell performance toner
iontophoresisanti aging solution i
u-max whitening functional essence
shelo nabel crema baba de caracol
sol mouthwash
equate scar
oz treehandmade by dorothy
ohl o2
healingcvs
dch scar
rite aid advanced scar gel
phyton therapy cleansing bar
bk cell 2step aqua toktok mask
eco face 9
bl vital serum
fucoidan hair tonic
blister armour anti-frictionmission
leaders mediu purifying salt pack
kenaf wet wipe kids
cetaphil baby soothe and protect cream
scarderm
vital fluid ii egf and fgf whitening serum
hasol revitalizing scalp ampoule
macoma senior premium cleanser
by pharmicell lab moisturizing face toning mist
revagain scalp tonic
luxury cell performance serum
version x scalp tonic
jilgyungyi (6 tablets)
m-rose seaweed hydrogel mask
newstem rx intensive
allantoin (ii)
bodyglide for her
reborncell aqua rich soft
miracle gyn (4 tablets)
vitamin c liquid
bl vital
atobos
black cavidiol mask
allantoin (usp-rs)
hahalady
cellpium vampire cleansing mask
shelo nabel jabon baba car
mederma for kids
dr young 2p blemish base spf35 pa
shelo nabel d b t cream
advanced derma therapy
reborncell aqua rich pure skin
baby wipes with allantoin
sheffield advanced scar gel
skinceuticals advanced scar control skin protectant
scar geladvanced formula
polyactil n
secretipss scalp hair essential tonic plus
scarcvs
purple
lycoris rubus whitening moisturizing
mulberry serum
bioxidea element 48 natura gold mask
scar care
healing head to toe
pelo baum brow brow
gene 16 whitening factor
fucoidan skincure
by pharmicell lab luxury cell performance serum
ramosu the witches cream pack gold
bodyglide anti chafe balm
mulberry toner
pelo baum hair revitalizing
seuk
rite aid scar
target advanced scar gel
secret gyno (10 tablets)
advanced scar gel
gmdansu eye serum
burn-b gone otc
shelo nabel cacao skin protectan
hairjoy msm scalp essence
hyundae meditech bio hair solu tion erua do
gmdansu skin
skin barista rice bran cleansing foam
original power whitening and lineless ampoule
vetracare pet liquid bandage
fucoidan essence
alra therapy
u-max multi bb
scar reducerintensive herbal and nutrient
m-rose seaweed lifting revitalizing
drs. pharmacy scar cream
allantoin .4%
allantoin-0.5%
vital fluid iv nano gold serum
the prestige essence
naaman
qc scar
mederma advanced scar
sbs 41 medicated cream
anti-chafe stickpro series
Z104486690

Research Excerpts

Overview

Allantoin is a nitrogenous compound derived from purine catabolism that contributes to nitrogen recycling in plants. Allantoinase acts as a key enzyme for the biogenesis and degradation of ureides by catalyzing the conversion of (S)-allantoin into allantoate, the final s.

ExcerptReferenceRelevance
"Allantoin is an important fine chemical that can be widely used in pharmaceutical, cosmetic and agricultural industries. "( Biosynthesis of allantoin in Escherichia coli via screening a highly effective urate oxidase.
Shen, X; Sun, X; Wang, J; Yan, Y; Yuan, Q; Zhang, F, 2022
)
2.51
"Allantoin is a good source of ammonium for many organisms, and in Escherichia coli it is utilized under anaerobic conditions. "( E. coli allantoinase is activated by the downstream metabolic enzyme, glycerate kinase, and stabilizes the putative allantoin transporter by direct binding.
Babu, M; Goodacre, N; Hosseinnia, A; Kim, S; Palsson, B; Rodionova, IA; Saier, MH; Uetz, P; Zhang, L; Zhang, Z, 2023
)
2.79
"Allantoin is a nitrogen metabolite with significant potential to mediate plant defense responses under salinity. "( Allantoin alleviates chromium phytotoxic effects on wheat by regulating osmolyte accumulation, secondary metabolism, ROS homeostasis and nutrient acquisition.
Alam, R; Ali, S; Ashraf, MA; Hussain, I; Rasheed, R, 2023
)
3.8
"Allantoin is an excellent biomarker of oxidative stress in humans as the main product of uric acid oxidation by reactive oxygen species. "( Rapid and reliable HILIC-MS/MS method for monitoring allantoin as a biomarker of oxidative stress.
Hasikova, L; Kalikova, K; Kozlik, P; Stiburkova, B; Zavada, J, 2020
)
2.25
"Allantoin is a nitrogenous compound derived from purine catabolism that contributes to nitrogen recycling in plants. "( Exogenous allantoin increases Arabidopsis seedlings tolerance to NaCl stress and regulates expression of oxidative stress response genes.
Irani, S; Todd, CD, 2018
)
2.33
"Allantoin is a key target metabolite for improving nitrogen homeostasis under stress."( Opposite fates of the purine metabolite allantoin under water and nitrogen limitations in bread wheat.
Baumann, U; Casartelli, A; Erban, A; Heuer, S; Hoefgen, R; Jayasinghe, NS; Melino, VJ; Mendis, H; Okamoto, M; Riboni, M; Roessner, U; Suchecki, R; Watanabe, M; Zuther, E, 2019
)
1.5
"Allantoin is a metabolic intermediate of purine catabolism that often accumulates in stressed plants. "( Allantoin, a stress-related purine metabolite, can activate jasmonate signaling in a MYC2-regulated and abscisic acid-dependent manner.
Akiyoshi, N; Egusa, M; Hirayama, T; Ishiga, Y; Kaminaka, H; Konishi, T; Matsuura, T; Mori, IC; Sakamoto, A; Shimada, H; Takagi, H; Watanabe, S, 2016
)
3.32
"Allantoin is a final product of L. sericata purine catabolism."( Urate Oxidase produced by Lucilia sericata medical maggots is localized in Malpighian tubes and facilitates allantoin production.
Baumann, A; Franta, Z; Lehmann, R; Skaljac, M; Vilcinskas, A, 2017
)
1.39
"Allantoinase acts as a key enzyme for the biogenesis and degradation of ureides by catalyzing the conversion of (S)-allantoin into allantoate, the final step in the ureide pathway. "( Crystal structure of metal-dependent allantoinase from Escherichia coli.
Ahn, JH; Chung, J; Kim, K; Kim, MI; Rhee, S, 2009
)
2.07
"Allantoin is a heterocyclic organic compound. "( Final report of the safety assessment of allantoin and its related complexes.
Alan Andersen, F; Becker, LC; Belsito, DV; Bergfeld, WF; Klaassen, CD; Marks, JG; Shank, RC; Slaga, TJ; Snyder, PW, 2010
)
2.07
"Allantoinase is a suspected dinuclear metalloenzyme that catalyzes the hydrolytic cleavage of the five-member ring of allantoin (5-ureidohydantoin) to form allantoic acid. "( Metal ion dependence of recombinant Escherichia coli allantoinase.
Hausinger, RP; Mulrooney, SB, 2003
)
2.01
"Allantoin is a nonenzymatic oxidative product of uric acid in human."( Uric acid and allantoin levels in Down syndrome: antioxidant and oxidative stress mechanisms?
Aruoma, OI; Duracková, Z; Garaiová, I; Kalnovicová, T; Korytár, P; Muchová, J; Pueschel, S; Sustrová, M; Zitnanová, I, 2004
)
1.41
"Allantoinase is a key enzyme for biogenesis and degradation of these ureide compounds."( Functional characterization of allantoinase genes from Arabidopsis and a nonureide-type legume black locust.
Han, KH; Yang, J, 2004
)
1.33
"Allantoin is a vegetable drug, poorly water-soluble (1:300), isolated from roots of Symphytum off."( [Physical and chemical characterization of allantoin-beta-cyclodextrin inclusion complex].
Gafiţanu, C; Macocinschi, D; Popescu, C; Singurel, G,
)
1.12
"Allantoin (All) is an oxidative end product of purines in mammals. "( Simultaneous determination of allantoin, hypoxanthine, xanthine, and uric acid in serum/plasma by CE.
Caussé, E; Couderc, F; Dirat, B; Negre-Salvayre, A; Pradelles, A; Salvayre, R, 2007
)
2.07
"1. Allantoin racemase is a novel enzyme which catalyzes the conversion of S(+)-and R(minus)-allantoin into the racemate. "( Allantoin racemase: a new enzyme from Pseudomonas species.
Van der Drift, C; Van der Drift, L; Vogels, GD, 1975
)
2.32

Effects

Allantoin has been reported as a promising biomarker for monitoring of oxidative stress in humans. Allantoin is widely utilized in a variety of topical pharmaceuticals and cosmetics.

ExcerptReferenceRelevance
"Allantoin has anti-inflammatory and wound healing properties."( Allantoin improves histopathological evaluations in a rat model of gastritis.
Eslami-Farsani, M; Hatami-Shahmir, A; Moslehi, A, 2018
)
2.64
"Allantoin has peripheral antinociceptive activity that involves the opioid receptor and ATP-sensitive K(+)channels."( Antinociceptive and anti-inflammatory effects of Memora nodosa and allantoin in mice.
Costa, EA; de Paula, JR; Florentino, IF; Galdino, PM; Lino, RC; Martins, JLR; Silva, DM; Silva, DPB; Tresvenzol, LMF, 2016
)
1.39
"Allantoin has been reported as a promising biomarker for monitoring of oxidative stress in humans and widely utilized in a variety of topical pharmaceuticals and cosmetics. "( Chemiluminescence of Lucigenin-Allantoin and Its Application for the Detection of Allantoin.
Halawa, MI; Kitte, SA; Liu, Z; Lou, B; Saqib, M; Xu, G, 2017
)
2.18
"Allantoin has also a chemical structure similar to metformin; both belong to guanidinium derivative."( Plasma glucose-lowering action of allantoin is induced by activation of imidazoline I-2 receptors in streptozotocin-induced diabetic rats.
Chen, LJ; Cheng, JT; Cheng, KC; Lin, KC; Wen, YJ; Yeh, LR, 2012
)
1.38
"Allantoin transport has not been described in the Brassicaceae."( UPS1 and UPS2 from Arabidopsis mediate high affinity transport of uracil and 5-fluorouracil.
Desimone, M; Frommer, WB; Hewitt, M; Kunze, R; Ludewig, U; Schmidt, A; Slocum, RD; Su, YH; Warner, S, 2004
)
1.04

Actions

Allantoin increases the contents of delphinidin-based anthocyanin 3-glucosides in berry skins. Allantoin is used to suppress protein aggregation without decreasing the melting temperature.

ExcerptReferenceRelevance
"Allantoin showed an increase in lipogenesis was recorded as a hepatic energy targeting muscles."( Allantoin may modulate aging impairments, symptoms and cancers.
El-Sonbaty, S; Marzook, E; Marzook, F, 2021
)
2.79
"Allantoin seems to increase the contents of delphinidin-based anthocyanin 3-glucosides in berry skins through the upregulation of F3'5'H gene that drives the synthesis of delphinidin-based anthocyanin 3-glucosides, compared with control berry skins."( Exogenous allantoin improves anthocyanin accumulation in grape berry skin at early stage of ripening.
Enoki, S; Moriyama, A; Nojiri, M; Suzuki, S; Watanabe, G, 2020
)
1.68
"Allantoin is used to suppress protein aggregation without decreasing the melting temperature. "( Effects of allantoin and dimethyl sulfoxide on the thermal aggregation of lysozyme.
Arakawa, T; Hirano, A; Nishinami, S; Shiraki, K, 2018
)
2.31

Treatment

Allantoin treatment (3 or 10 mg/kg, for 7 days) increased the expression levels of phosphorylated phosphatidylinositide 3-kinase (PI3K) Allantoin led to significant reduction in the levels of Ig(immunoglobulin)E and T-helper-2-type cytokines, such as IL(interleukin)-4 and IL-5.

ExcerptReferenceRelevance
"Allantoin treatment of Col-0 seeds increases superoxide dismutase activity causing an enhanced seed germination and seedling growth following Cd exposure."( There is a direct link between allantoin concentration and cadmium tolerance in Arabidopsis.
Nourimand, M; Todd, CD, 2019
)
1.52
"Allantoin treatment (3 or 10 mg/kg, for 7 days) also increased the expression levels of phosphorylated phosphatidylinositide 3-kinase (PI3K), phosphorylated protein kinase B (Akt) and phosphorylated glycogen synthase kinase-3β (GSK-3β)."( Effects of allantoin on cognitive function and hippocampal neurogenesis.
Ahn, YJ; Gao, Q; Jang, DS; Kim, HJ; Kwon, G; Lee, HE; Park, SJ; Ryu, JH; Woo, H, 2014
)
1.51
"Allantoin treatment led to significant reduction in the levels of Ig(immunoglobulin)E and T-helper-2-type cytokines, such as IL(interleukin)-4 and IL-5, in bronchoalveolar lavage (BAL) fluid."( Protective effects of allantoin against ovalbumin (OVA)-induced lung inflammation in a murine model of asthma.
Jung, D; Kim, JH; Lee, H; Lee, JA; Lee, MY; Lee, NH; Seo, CS; Shin, HK, 2010
)
1.4
"The treatment with allantoin (40, 60 and 80mg/kg p.o.) produced a dose-dependent antinociceptive effect in both phases of formalin-induced nociception test; allantoin (60mg/kg) was not able to increase the latency time in tail flick-test."( Antinociceptive and anti-inflammatory effects of Memora nodosa and allantoin in mice.
Costa, EA; de Paula, JR; Florentino, IF; Galdino, PM; Lino, RC; Martins, JLR; Silva, DM; Silva, DPB; Tresvenzol, LMF, 2016
)
0.99

Toxicity

ExcerptReferenceRelevance
" No unexpected or severe adverse events occurred in the Contractubex-treated patients."( Safety and efficacy of local administration of contractubex to hypertrophic scars in comparison to corticosteroid treatment. Results of a multicenter, comparative epidemiological cohort study in Germany.
Basten, R; Beuth, J; Hunzelmann, N; Noehle, M; Schneider, B; Van Leendert, R,
)
0.13
" Concerning safety, Contractubex treatment was associated with significantly less adverse events (e."( Safety and efficacy of local administration of contractubex to hypertrophic scars in comparison to corticosteroid treatment. Results of a multicenter, comparative epidemiological cohort study in Germany.
Basten, R; Beuth, J; Hunzelmann, N; Noehle, M; Schneider, B; Van Leendert, R,
)
0.13
" No adverse effects or superimposed infections were reported."( A randomized controlled trial to compare the effectiveness and safety of adsorbent lotion containing tapioca starch, spent grain wax, Butyrospermum parkii extract, argania spinosa kernel oil, aloe barbadensis, rosehip oil, and allantoin with a low-potency
Kulthanan, K; Leeyaphan, C; Lertrujiwanit, K; Matthapan, L; Pattaravadee, S; Prasong, W; Supcharoenkul, S; Suphatsathienkul, P; Trakanwittayarak, S; Varothai, S, 2022
)
0.91
" The lotion was safe and produced excellent pruritus reduction."( A randomized controlled trial to compare the effectiveness and safety of adsorbent lotion containing tapioca starch, spent grain wax, Butyrospermum parkii extract, argania spinosa kernel oil, aloe barbadensis, rosehip oil, and allantoin with a low-potency
Kulthanan, K; Leeyaphan, C; Lertrujiwanit, K; Matthapan, L; Pattaravadee, S; Prasong, W; Supcharoenkul, S; Suphatsathienkul, P; Trakanwittayarak, S; Varothai, S, 2022
)
0.91

Bioavailability

ExcerptReferenceRelevance
"Solubility and bioavailability of poorly water-soluble drugs have been improved by the preparation as cyclodextrin inclusion complexes."( [Physical and chemical characterization of allantoin-beta-cyclodextrin inclusion complex].
Gafiţanu, C; Macocinschi, D; Popescu, C; Singurel, G,
)
0.39
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

TEI-6720 and allopurinol showed similar dose-response curves for the decrease in uric acid or allantoin concentration, and the associated increase in xanthine concentration. Salicylate (an anion) and quinine (a cation) inhibit the uptake of the para-aminohippuric acid and tetraethylammonium bromide.

ExcerptRelevanceReference
" The results obtained here demonstrate the possibility of an occurence of the majority of the analyzed substances as metastable polymorphic modifications in solid dosage forms."( IR analysis of crystalline samples of some urea derivatives.
Halkiewicz, J; Kaliszan, R,
)
0.13
" Salicylate (an anion) and quinine (a cation), in dosage which inhibited allantoin uptake, also inhibit the uptake of the para-aminohippuric acid (an anion) and tetraethylammonium bromide (a cation)."( Renal handling of [14C]allantoin in the rabbit.
Roch-Ramel, F; Schäli, C, 1980
)
0.8
" In addition, TEI-6720 and allopurinol showed similar dose-response curves for the decrease in uric acid or allantoin concentration, and the associated increase in xanthine concentration, indicating that TEI-6720 and allopurinol have similar pharmacological characteristics although the dosage required differs."( A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats.
Horiuchi, H; Kaneko, H; Kasahara, Y; Kobayashi, M; Komoriya, K; Kondo, S; Nishimura, S; Ota, M, 1999
)
0.52
"The objectives of the present study were to investigate the recovery of [14C]allantoin in urine of sheep dosed intravenously and degradation of allantoin by rumen micro-organisms."( Variation between sheep in renal excretion of [14C]allantoin.
Chen, XB; Hovell, FD; Kyle, DJ; Prasitkusol, P; Ørskov, ER, 2002
)
0.8
"An ion-pair high-performance liquid chromatography (HPLC) method has been developed for the simultaneous determination of chondroitin sulfate sodium (CSS), allantoin and pyridoxine hydrochloride (VB(6)) in a commercial eye drops dosage form."( Simultaneous determination of chondroitin sulfate sodium, allantoin and pyridoxine hydrochloride in pharmaceutical eye drops by an ion-pair high-performance liquid chromatography.
Hu, X; Jin, P; Ma, J; Sun, C; Wu, X; Zou, D, 2009
)
0.79
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (14 Items)

ItemProcessFrequency
en:open-beauty-factscore-ingredient13
Open Beauty Factscore-ingredient10
Non food productscore-ingredient4
Non alimentairecore-ingredient4
Non-Food-Produktecore-ingredient2
Open Products Factscore-ingredient1
Cosmetic lotioncore-ingredient1
en:Fersen Cremecore-ingredient1
Cosmetiquecore-ingredient1
en:toothpastecore-ingredient1
Mascarilla Facial de celulosacore-ingredient1
Productos no alimenticioscore-ingredient1
Serumcore-ingredient1
en:skinvarecore-ingredient1

Roles (4)

RoleDescription
vulneraryA drug used in treating and healing of wounds.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
imidazolidine-2,4-dioneAn imidazolidinone with oxo groups at position 2 and 4.
ureas
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (7)

PathwayProteinsCompounds
Glycolate and Glyoxylate Degradation1522
Urate Degradation to Ureidoglycolate613
Urate Degradation to Glyoxylate714
Ureide biosynthesis017
Biochemical pathways: part I0466
Allantoin degradation616
ureide biogenesis417

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency7.07950.003245.467312,589.2998AID2517
RGS12Homo sapiens (human)Potency12.58930.794310.991425.1189AID2390
GLI family zinc finger 3Homo sapiens (human)Potency19.59460.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency11.17140.000221.22318,912.5098AID743040; AID743042; AID743054
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency24.08920.000657.913322,387.1992AID1259377
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency19.49710.01237.983543.2770AID1645841
estrogen nuclear receptor alphaHomo sapiens (human)Potency52.31610.000229.305416,493.5996AID743069; AID743075; AID743079
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency14.29990.001723.839378.1014AID743083
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency89.12510.354828.065989.1251AID504847
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency60.50940.000323.4451159.6830AID743066
Alpha-synucleinHomo sapiens (human)Potency5.62340.56239.398525.1189AID652106
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (77)

Processvia Protein(s)Taxonomy
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (26)

Processvia Protein(s)Taxonomy
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (22)

Processvia Protein(s)Taxonomy
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (60)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID589667Induction of NGF production in rat C6 cells at 20 uM after 24 hrs by ELISA relative to untreated control2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Furostanol saponins from the rhizomes of Dioscorea japonica and their effects on NGF induction.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID589668Cytotoxicity against rat C6 cells assessed as viable cells at 20 uM after 24 hrs by MTT assay2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Furostanol saponins from the rhizomes of Dioscorea japonica and their effects on NGF induction.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID453747Inhibition of Escherichia coli recombinant N-terminal hexahistidine-tagged CTP synthetase expressed in Escherichia coli BL21 (DE3) assessed as inhibition of CTP formation by continuous spectrophotometric assay in presence of 10 mM L-glutamine and 0.15 mM 2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Inhibition of CTP synthase from Escherichia coli by xanthines and uric acids.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID453744Inhibition of Escherichia coli recombinant N-terminal hexahistidine-tagged CTP synthetase expressed in Escherichia coli BL21 (DE3) assessed as inhibition of CTP formation by continuous spectrophotometric assay in presence of 150 mM NH4Cl2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Inhibition of CTP synthase from Escherichia coli by xanthines and uric acids.
AID1355607Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells pretreated for 1 hr followed by LPS-stimulation and measured after 24 hrs by Griess assay2018Journal of natural products, 07-27, Volume: 81, Issue:7
Chemical Constituents of Apios americana Tubers and Their Inhibitory Activities on Nitric Oxide Production in Lipopolysaccharide-Stimulated RAW 264.7 Macrophages.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,087)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990473 (43.51)18.7374
1990's161 (14.81)18.2507
2000's167 (15.36)29.6817
2010's211 (19.41)24.3611
2020's75 (6.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 71.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index71.21 (24.57)
Research Supply Index7.09 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index151.47 (26.88)
Search Engine Supply Index2.39 (0.95)

This Compound (71.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials70 (6.19%)5.53%
Reviews38 (3.36%)6.00%
Case Studies12 (1.06%)4.05%
Observational1 (0.09%)0.25%
Other1,009 (89.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Investigation Into the Efficacy of Herpecin L at Reducing the Frequency and Severity of Cold Sores [NCT05796635]80 participants (Actual)Interventional2023-01-04Completed
The Efficacy of Prophylactic Use of Extract of Allium Cepae, Allantoin and Heparin in Patients With Proven Scar Development After Excision of Previous Scar [NCT02708628]120 participants (Actual)Interventional2015-12-31Completed
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled, Parallel Study of Dexamethasone-Allantoin-Metronidazole (DAM) Solution in the Treatment of Post-Operative Ileus (POI) in Subjects Undergoing Abdominal Operation [NCT01863407]Phase 3480 participants (Anticipated)Interventional2013-04-30Recruiting
Open-label, Pilot Study to Investigate the Safety and Tolerability of Alwextin 3.0% Cream in the Treatment of Epidermolysis Bullosa [NCT00825565]Phase 28 participants (Actual)Interventional2009-02-28Completed
Retrospective Study to Evaluate the Safety of Sebryl® and / or Sebryl Plus® in the Treatment of Seborrheic Dermatitis and Psoriasis of the Scalp in Routine Medical Practice. [NCT05105139]90 participants (Actual)Observational2021-11-29Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00825565 (4) [back to overview]Blister/Erosion Reduction Based on Change in Body Surface Area (BSA) Coverage
NCT00825565 (4) [back to overview]Target Wound Size Reduction or Closure
NCT00825565 (4) [back to overview]Physician Assessment of Individual Signs
NCT00825565 (4) [back to overview]Physician Global Assessment of Severity (PGAS)

Blister/Erosion Reduction Based on Change in Body Surface Area (BSA) Coverage

"A common measure of the degree of involvement in skin disease is the Body Surface Area Index (BSAI). This measure is also commonly used in psoriasis studies. It is a global measure of disease spread with weighting factors." (NCT00825565)
Timeframe: baseline and then every 4 weeks for a total of 12 weeks

Interventionpercentage of BSA involvement (Mean)
Baseline assessmentWeek 4 assessmentWeek 8 assessmentWeek 12 assessment
Allantoin 3% Cream57.2539.4027.2525.45

[back to top]

Target Wound Size Reduction or Closure

"EB patients may have chronic wounds which are resistant to healing. Wound size may be very large and the probability of total wound closure with currently available treatments is unlikely. Reduction in the size of wounds may be clinically important to the rate of infection and pain. If a patient has a reduction in the size of wounds which are refractory to healing, this may be seen as a positive outcome. Wound size reduction is one of the primary assessments used to determine the efficacy of the study cream.~Wounds which had been present for at least several weeks prior to study entry were measured by using VISITRAK Digital, a Smith and Nephew wound tracing and measurement system that will calculate the length and width of the lesion (class 1 medical device; FDA listing designation E142354FDA). Only one target lesion per patient was used for the study assessment. At each subsequent study until the final visit, the target lesion was evaluated using VISITRAK Digital." (NCT00825565)
Timeframe: baseline and then every 4 weeks for a total of 12 weeks

Interventionnumber of unhealed target wounds (Number)
Baseline assessmentWeek 12 assessment
Allantoin 3% Cream81

[back to top]

Physician Assessment of Individual Signs

"In addition to skin blistering and erosions, people with EB experience other symptoms, such as erythema on unblistered skin, wound oozing, weeping, and crusting. These symptoms may vary with area of the body evaluated.~This scale evaluates the following signs: Blistering and erosions, oozing/weeping/crusting, pruritis, erythema on unblistered surrounding skin, pain, milia Each of these signs will be scored in 4 body areas: head/neck, upper limbs, trunk, lower limbs The following scale is used:0 = clear 1 = almost clear 2 = mild 3 = moderate 4 = severe" (NCT00825565)
Timeframe: baseline and at 12 weeks

InterventionParticipants (Count of Participants)
Pain-Baseline72102144Pain-Baseline72102143Pain-Baseline72102142Pain-Baseline72102145Pain-Month 372102143Pain-Month 372102142Pain-Month 372102145Pain-Month 372102144Pruritis-Baseline72102142Pruritis-Baseline72102144Pruritis-Baseline72102143Pruritis-Baseline72102145Pruritus-Month 372102142Pruritus-Month 372102145Pruritus-Month 372102143Pruritus-Month 372102144Blisters/Erosions-Baseline72102143Blisters/Erosions-Baseline72102145Blisters/Erosions-Baseline72102142Blisters/Erosions-Baseline72102144Blisters/Erosions- Month 372102143Blisters/Erosions- Month 372102142Blisters/Erosions- Month 372102144Blisters/Erosions- Month 372102145Oozing/Weeping/Crusting-Baseline72102142Oozing/Weeping/Crusting-Baseline72102143Oozing/Weeping/Crusting-Baseline72102144Oozing/Weeping/Crusting-Baseline72102145Oozing/Weeping/Crusting- Month 372102142Oozing/Weeping/Crusting- Month 372102144Oozing/Weeping/Crusting- Month 372102145Oozing/Weeping/Crusting- Month 372102143Erythema-Baseline72102142Erythema-Baseline72102143Erythema-Baseline72102144Erythema-Baseline72102145Erythema- Month 372102142Erythema- Month 372102143Erythema- Month 372102144Erythema- Month 372102145Milia-Baseline72102142Milia-Baseline72102143Milia-Baseline72102144Milia-Baseline72102145Milia- Month 372102144Milia- Month 372102145Milia- Month 372102143Milia- Month 372102142
ClearAlmost ClearMildModerateSevere
Lower Limbs0
Lower Limbs1
Lower Limbs2
Lower Limbs4
Head/Neck5
Lower Limbs3
Head/Neck1
Upper Limbs1
Head/Neck4
Upper Limbs4
Trunk3
Lower Limbs5
Head/Neck0
Upper Limbs0
Head/Neck2
Trunk1
Upper Limbs2
Trunk2
Trunk0
Upper Limbs5
Head/Neck3
Upper Limbs3
Trunk4
Head/Neck7
Upper Limbs8
Trunk8
Lower Limbs8

[back to top]

Physician Global Assessment of Severity (PGAS)

"The FDA has suggested that a global measure of severity might be the best way to assess EB from visit to visit. Assessment score may be influenced by other clinical observations in addition to the percentage of body affected by blistering and erosions. The assessment was intended to be a global impression.~This scale produced a score with the following correlations:~0 = clear (no blistering/erosions) 1-2 = almost clear (infrequent blistering and erosions) 3-4 = mild disease (up to 15% of body affected) 5-6 = moderate disease (between 16-25% of body affected) 7-8 = severe disease (between 26-50% of body affected) 9-10 = very severe disease (greater than 50% of body affected)" (NCT00825565)
Timeframe: baseline and then every 4 weeks for a total of 12 weeks

InterventionParticipants (Count of Participants)
Baseline72102141Month 172102141Month 272102141Month 372102141
PGAS score of 1PGAS score of 2PGAS score of 3PGAS score of 4PGAS score of 5PGAS score of 6PGAS score of 7PGAS score of 8PGAS score of 9PGAS score of 10
Alwextin Cream0
Alwextin Cream1
Alwextin Cream2
Alwextin Cream3

[back to top]